Early clinical signal in a new indication (gynecologic cancers) is encouraging but remains highly speculative given Phase 1 limitations and lack of FDA approval for solid tumors. Monitor for Phase 2 initiation and any partnership or financing updates.
Price Chart
Executive Summary
Citius Oncology issued a press release highlighting Phase 1 data from an investigator-initiated study of LYMPHIR (denileukin diftitox-cxdl) in combination with pembrolizumab in recurrent/refractory gynecologic malignancies, presented at ASCO 2026. The data showed a 24% ORR (5/21 evaluable patients), a 33% ORR in checkpoint-inhibitor-pretreated endometrial cancer, and a median PFS of 20.5 months among the 48% of patients achieving clinical benefit. This is early-stage, investigator-initiated data not powered for efficacy, and LYMPHIR is not FDA-approved for this indication.
Key Facts
- Phase 1 data presented May 30, 2026 at ASCO Annual Meeting (Abstract #2564) for LYMPHIR + pembrolizumab in recurrent/refractory gynecologic malignancies.
- 24% ORR among 21 efficacy-evaluable patients (5 partial responses); median duration of response not yet reached (median 21.1 months).
- 33% ORR in endometrial cancer patients previously treated with checkpoint inhibitors, including one ongoing response >3 years.
- 48% of evaluable patients (10/21) achieved clinical benefit; median PFS of 20.5 months in that subgroup.
- Safety: 1 reversible Grade 3 capillary leak syndrome at highest dose; no new safety signals; MTD not reached.
- LYMPHIR is not FDA-approved for gynecologic malignancies or any solid tumor; Phase 1 study not designed/powered for efficacy.
- A Phase 2 expansion study is being planned in gynecologic cancers.
- LYMPHIR was FDA-approved and launched in the U.S. in December 2025 for relapsed/refractory Stage I-III CTCL.
Financial Impact
No financial data provided in the filing. The press release contains no revenue, EPS, guidance, or deal figures.
Risk Factors
- Phase 1 data may not be predictive of larger or later-stage study results.
- LYMPHIR is not approved for gynecologic malignancies; regulatory path uncertain.
- Company faces going-concern risk and Nasdaq continued listing compliance concerns as noted in forward-looking statements.
- Heavily pre-treated patient population (median 5 prior therapies) limits generalizability.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-063530 |
| Document: ea0292903-8k_citius.htm | 0001213900-26-063530 |
| Document: 0001213900-26-063530-index-headers.html | 0001213900-26-063530 |
| Document: 0001213900-26-063530-index.html | 0001213900-26-063530 |
| Document: 0001213900-26-063530.txt | 0001213900-26-063530 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $0.6000 | awaiting T+5 | — | $0.5957 (−0.72%) |
Oct 26, 2026 today | Press Release | $0.6072 | awaiting T+5 | — | $0.5957 (−1.89%) |
Oct 23, 2026 3d ago | 8-K | $0.5795 | awaiting T+5 | — | $0.5957 (−2.80%) |
Aug 12, 2026 10w ago | 8-K | $0.8115 $0.7525 | ▼ −7.27% | ▼ −6.83% | $0.5957 (−26.59%) |
Aug 5, 2026 11w ago | 8-K | $0.7850 $0.8115 | ▲ +3.38% | ▲ +3.03% | $0.5957 (−24.11%) |
Jun 8, 2026 20w ago | EFFECT | $0.7999 $0.6802 | ▲ +14.96% | ▲ +17.08% | $0.5957 (+25.53%) |
Jun 1, 2026 21w ago | 8-K | $0.7830 $0.7200 | ▼ −8.05% | ▼ −5.08% | $0.5957 (−23.92%) |
May 29, 2026 21w ago | S-3 | $0.7920 $0.7800 | ▲ +1.52% | ▼ −1.24% | $0.5957 (+24.79%) |
May 15, 2026 23w ago | 8-K | $0.8290 $0.8600 | ▲ +3.74% | ▲ +2.12% | $0.5957 (−28.14%) |
Mar 3, 2026 33w ago | EFFECT | $1.06 $1.01 | ▼ −5.19% | ▼ −4.71% | $0.5957 (−43.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers